The glob­al ri­val­ry for top sci­en­tif­ic tal­ent in bio­phar­ma R&D is about to get a lot hot­ter

Tony Ho was a key play­er in As­traZeneca’s on­col­o­gy R&D group, help­ing lead suc­cess­ful Phase III stud­ies for Lyn­parza and Imfinzi — two of its top new drugs. But the se­nior vice pres­i­dent has moved on to an­oth­er com­pa­ny now, As­traZeneca con­firms for me, un­der­scor­ing a sig­nif­i­cant mi­gra­tion of top R&D tal­ent that will soon see grow­ing com­pe­ti­tion among the top play­ers for the best sci­en­tists in drug de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER